DE69728914D1 - Pharmazeutische Zusammensetzung gegen durch Papillomaviren verursachte Tumoren und Infektionen - Google Patents

Pharmazeutische Zusammensetzung gegen durch Papillomaviren verursachte Tumoren und Infektionen

Info

Publication number
DE69728914D1
DE69728914D1 DE69728914T DE69728914T DE69728914D1 DE 69728914 D1 DE69728914 D1 DE 69728914D1 DE 69728914 T DE69728914 T DE 69728914T DE 69728914 T DE69728914 T DE 69728914T DE 69728914 D1 DE69728914 D1 DE 69728914D1
Authority
DE
Germany
Prior art keywords
papillomaviruses
pharmaceutical composition
infections caused
composition against
against tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69728914T
Other languages
English (en)
Other versions
DE69728914T2 (de
Inventor
Jean-Marc Balloul
Nadine Bizouarne
Marie Paule Kieny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9494633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69728914(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene SA filed Critical Transgene SA
Publication of DE69728914D1 publication Critical patent/DE69728914D1/de
Application granted granted Critical
Publication of DE69728914T2 publication Critical patent/DE69728914T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
DE69728914T 1996-07-30 1997-07-29 Pharmazeutische Zusammensetzung gegen durch Papillomaviren verursachte Tumoren und Infektionen Expired - Lifetime DE69728914T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9609584A FR2751879B1 (fr) 1996-07-30 1996-07-30 Composition pharmaceutique contre les tumeurs et infections a papillomavirus
FR9609584 1996-07-30

Publications (2)

Publication Number Publication Date
DE69728914D1 true DE69728914D1 (de) 2004-06-03
DE69728914T2 DE69728914T2 (de) 2005-04-07

Family

ID=9494633

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69706825T Expired - Lifetime DE69706825T3 (de) 1996-07-30 1997-07-29 Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
DE69728914T Expired - Lifetime DE69728914T2 (de) 1996-07-30 1997-07-29 Pharmazeutische Zusammensetzung gegen durch Papillomaviren verursachte Tumoren und Infektionen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69706825T Expired - Lifetime DE69706825T3 (de) 1996-07-30 1997-07-29 Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen

Country Status (12)

Country Link
EP (2) EP1149910B1 (de)
JP (2) JP4070815B2 (de)
AT (2) ATE205881T1 (de)
AU (1) AU736720B2 (de)
CA (1) CA2234263C (de)
DE (2) DE69706825T3 (de)
DK (2) DK1149910T3 (de)
ES (2) ES2163795T5 (de)
FR (1) FR2751879B1 (de)
HK (1) HK1043809B (de)
PT (2) PT1149910E (de)
WO (1) WO1998004705A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
CA2335506A1 (en) * 1998-06-26 2000-01-06 Aventis Pasteur Mucosal targeting immunisation
DK2029756T3 (en) * 2006-06-20 2017-02-13 Transgene Sa PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS
PL2382474T3 (pl) 2009-01-20 2015-08-31 Transgene Sa Rozpuszczalny ICAM-1 jako biomarker do prognozowania odpowiedzi terapeutycznej
KR20110138354A (ko) 2009-03-24 2011-12-27 트랜스진 에스.에이. 환자를 모니터링하기 위한 바이오마커
SG175060A1 (en) 2009-04-17 2011-11-28 Transgene Sa Biomarker for monitoring patients
CA2760465A1 (en) 2009-05-12 2010-11-18 Transgene Sa Method for orthopoxvirus production and purification
HUE028240T2 (en) 2009-07-10 2016-12-28 Transgene Sa Biomarker Patient Selection and Related Procedures
EP2456461A1 (de) 2009-07-21 2012-05-30 Transgene SA Enzymatische zusammensetzung für den aufschluss von hühnerembryos
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
DK3226894T3 (da) 2014-12-01 2019-10-21 Transgene Sa Stabile flydende vacciniavirus-formuleringer
FR3042121A1 (fr) * 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
US11306292B2 (en) 2017-05-15 2022-04-19 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2018211419A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
AU2019336940A1 (en) 2018-09-06 2021-03-11 Bavarian Nordic A/S Storage improved poxvirus compositions
WO2021180943A1 (en) 2020-03-12 2021-09-16 Bavarian Nordic A/S Compositions improving poxvirus stability

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643817B1 (fr) * 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
IE910909A1 (en) † 1990-03-20 1991-09-25 Behringwerke Ag Seroreactive epitopes of human Papillomavirus (HPV) 16¹proteins
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
ATE332973T1 (de) * 1991-07-19 2006-08-15 Univ Queensland Polynukleotidabschnitt des hpv16-genoms
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide for vaccination against the umbilical cord virus
AU712714B2 (en) * 1994-10-03 1999-11-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule B7 gene in a recombinant virus expressing system
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique

Also Published As

Publication number Publication date
DK0862634T3 (da) 2002-01-21
FR2751879A1 (fr) 1998-02-06
HK1043809A1 (en) 2002-09-27
ES2163795T5 (es) 2006-07-16
HK1043809B (zh) 2004-12-03
WO1998004705A1 (fr) 1998-02-05
JP2000500662A (ja) 2000-01-25
EP1149910A1 (de) 2001-10-31
ATE265535T1 (de) 2004-05-15
ES2163795T3 (es) 2002-02-01
EP1149910B1 (de) 2004-04-28
JP4198735B2 (ja) 2008-12-17
AU736720B2 (en) 2001-08-02
ES2215805T3 (es) 2004-10-16
CA2234263C (fr) 2009-10-13
JP4070815B2 (ja) 2008-04-02
AU3855297A (en) 1998-02-20
DK1149910T3 (da) 2004-08-02
CA2234263A1 (fr) 1998-02-05
FR2751879B1 (fr) 1998-10-30
DE69706825T3 (de) 2006-08-24
JP2007254474A (ja) 2007-10-04
DE69706825T2 (de) 2002-05-02
DE69728914T2 (de) 2005-04-07
EP0862634B2 (de) 2006-03-01
EP0862634B1 (de) 2001-09-19
DK0862634T4 (da) 2006-05-08
EP0862634A1 (de) 1998-09-09
ATE205881T1 (de) 2001-10-15
PT1149910E (pt) 2004-09-30
PT862634E (pt) 2002-03-28
DE69706825D1 (de) 2001-10-25

Similar Documents

Publication Publication Date Title
DE69728914D1 (de) Pharmazeutische Zusammensetzung gegen durch Papillomaviren verursachte Tumoren und Infektionen
HK1036931A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients.
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
DE59205752D1 (de) Substituierte Biphenylpyridone als Angiotensin II Antagonisten
FI891361A (fi) Menetelmä farmaseuttisesti vaikuttavien aryylihydratsonien valmistamiseksi
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
UA50808C2 (uk) Композиція для лікування респіраторного дистрес-синдрому дорослих або респіраторного дистрес-синдрому новонароджених
DK1077941T3 (da) Forbindelser med væksthormonfrigörende egenskaber
CS156792A3 (en) Substituted diaminophthalimides and compounds analogous thereto
ATE401896T1 (de) Pharmazeutische zusammensetzungen mit tumor nekrose faktor und 2-methoxyestron-3-o-sulphamat als estrone sulphatasehemmern
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
KR960703863A (ko) 암 치료용 신규 비스-나프탈이미드(New Bis-naphthalimides for the Treatment of Cancer)
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
CA2111083A1 (en) Novel peptides, their preparation and use
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
DE60035133D1 (de) Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
EP1074264A4 (de) Inhibitoren für die gefässneubildung
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
YU46302A (sh) Supstituisani piroli
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
SE9401596D0 (sv) New compounds
TR200100354T2 (tr) NK-2 Antagonist hareketine sahip monosiklik bileşimler ve oluşumlar.
NZ505085A (en) Pharmaceutical compositions comprising bipapcitide monocarboxylate and/or bipapcitide dicarboxylate for imaging and treating thrombi
RU94019328A (ru) α- ГЕТЕРОАРИЛОКСИМЕТИЛКЕТОНЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ИНГИБИРУЮЩАЯ ИНТЕРЛЕЙКИН-1 - β -ПРОТЕАЗУ

Legal Events

Date Code Title Description
8364 No opposition during term of opposition